493 results on '"Szymonifka, Jackie"'
Search Results
102. High-dose proton-based radiation therapy in the management of spine chordomas: outcomes and clinicopathological prognostic factors
103. Abstract 17471: Cardiorenal Syndrome Patients With High NT-proBNP and Cystatin C Levels and Patients With Irreversible Cardiorenal Syndrome Identified by Persistently High Levels of Cystatin C Have Worse Outcomes in Cardiac Resynchronization Therapy: The BIOCRT Study
104. Abstract 16574: Heart Failure Biomarkers (NT-proBNP, Gal-3, sST2) Correlate With Right Ventricular Systolic Pressure and Provide Insight to Poor CRT Response: A BIOCRT Substudy
105. Utility of dual-source computed tomography in cardiac resynchronization therapy-DIRECT study.
106. Identification of Three Rheumatoid Arthritis Disease Subtypes by Machine Learning Integration of Synovial Histologic Features and RNA Sequencing Data.
107. Postoperative Myocardial Injury and Inflammation Is Not Blunted by a Trial of Atorvastatin in Orthopedic Surgery Patients.
108. Achieving target SBP for lowering the risk of major adverse cardiovascular events in persons with diabetes mellitus.
109. What Does the ASA Section on Statistical Consulting Mean to You?
110. Clinical characteristics and treatment outcomes of patients with metastatic, MET-amplified esophagogastric cancers.
111. Relationship of thoracic fat depots with coronary atherosclerosis and circulating inflammatory biomarkers
112. Computationally simple analysis of matched, outcome-based studies of ordinal disease states
113. DIAGNOSIS OF NECROTIC INTRAPLAQUE CORES BY DUAL ENERGY CORONARY COMPUTED TOMOGRAPHIC ANGIOGRAPHY IN VICTIMS OF SUDDEN CORONARY DEATH: VALIDATION TO A PATHOLOGIC GOLD STANDARD
114. A SIMPLE-TO-USE NOMOGRAM FOR PREDICTING 5-, 10- AND 15-YEAR SURVIVAL FOR ASYMPTOMATIC INDIVIDUALS UNDERGOING CORONARY ARTERY CALCIUM SCORING
115. Preliminary Results of a Phase II Trial of Proton Radiotherapy for Pediatric Rhabdomyosarcoma
116. Diagnostic performance of cardiac imaging methods to diagnose ischaemia-causing coronary artery disease when directly compared with fractional flow reserve as a reference standard: a meta-analysis.
117. Characterization and Prediction of Adverse Events from Intensive Chronic Heart Failure Management with and without NT-proBNP Guidance: Results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study
118. Surgical resection and intraoperative radiation therapy for locally recurrent rectal carcinoma.
119. Validation of the NSABP neoadjuvant rectal score (NAR) in a prospective phase II study evaluating an experimental regimen and a standard chemoradiation cohort with molecular genotyping.
120. INCREMENTAL VALUE OF CYSTATIN C BEYOND CONVENTIONAL MARKERS OF RENAL FUNCTION FOR PREDICTING CLINICAL RESPONSE IN PATIENTS RECEIVING CARDIAC RESYNCHRONIZATION THERAPY: THE BIOCRT STUDY
121. SUPERIORITY OF CORONARY SINUS CARDIAC BIOMARKER SAMPLING OVER PERIPHERAL VENOUS BLOOD FOR PROGNOSTICATION IN CARDIAC RESYNCHRONIZATION THERAPY: THE BIOCRT STUDY
122. O010 The relationship between intrathoracic fat depots, circulating inflammatory biomarkers and coronary artery disease suggests a local atherogenic effect of the pericoronary adipose tissue compartment
123. Head-to-Head Comparison of Serial Soluble ST2, Growth Differentiation Factor-15, and Highly-Sensitive Troponin T Measurements in Patients With Chronic Heart Failure
124. Outcomes of Breast Cancer in Brazil Related to Health Care Coverage: A Retrospective Cohort Study
125. Measurement of Novel Biomarkers to Predict Chronic Heart Failure Outcomes and Left Ventricular Remodeling
126. Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival
127. Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group–directed intergroup trial S9003
128. Mutational and Clinical Predictors of Pathologic Complete Response in the Treatment of Locally Advanced Rectal Cancer
129. β-Catenin Mutation Status and Outcomes in Sporadic Desmoid Tumors
130. Aortic distensibility and its relationship to coronary and thoracic atherosclerosis plaque and morphology by MDCT: Insights from the ROMICAT Trial
131. DNA mutation frequencies in metastatic small bowel adenocarcinoma (mSBA) in comparison to gastric (mGC), colon (mCC), and rectal cancer (mRC): Continuum or cutpoint?
132. FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience
133. Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: A 10-year single institution retrospective study
134. CORONARY SINUS LEVEL OF GALECTIN-3 IS A BETTER PREDICTOR THAN PERIPHERAL VENOUS LEVEL OF MAJOR ADVERSE CARDIAC EVENTS IN PATIENTS WITH CARDIAC RESYNCHRONIZATION THERAPY
135. SERIAL MEASUREMENT OF INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 7 PREDICTS CHRONIC HEART FAILURE OUTCOMES AND VENTRICULAR REMODELING: RESULTS FROM THE PROBNP OUTPATIENT TAILORED CHRONIC HEART FAILURE THERAPY (PROTECT) STUDY
136. CIRCULATING CONCENTRATIONS OF SOLUBLE ST2 IDENTIFY BENEFIT OF HIGH DOSE BETA BLOCKER IN CHRONIC HEART FAILURE: RESULTS FROM THE PROBNP OUTPATIENT TAILORED CHRONIC HEART FAILURE THERAPY (PROTECT) STUDY
137. SERIAL MEASUREMENT OF GALECTIN-3 PREDICTS CHRONIC HEART FAILURE OUTCOMES AND VENTRICULAR REMODELING: RESULTS FROM THE PROBNP OUTPATIENT TAILORED CHRONIC HEART FAILURE THERAPY (PROTECT) STUDY
138. Mutational analysis of locally advanced rectal cancer and response to neoadjuvant chemoradiation.
139. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
140. Prognostic Significance of DNA/Cig Flow Cytometry Assay in the ‘'era” of Novel Therapies in Multiple Myeloma (MM).
141. Prevalence and significance of subcentimeter hepatic lesions in patients with localized pancreatic adenocarcinoma
142. Basic Statistics.
143. Prognostic Factors and Outcomes of Patients with Myxofibrosarcoma
144. Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1
145. Proton radiotherapy for rhabomyosarcoma: Preliminary results from a multicenter prospective study.
146. Multicenter randomized phase II trial of cisplatin, irinotecan plus bevacizumab (PCA) versus docetaxel, cisplatin, irinotecan plus bevacizumab (TPCA) in patients (pts) with metastatic esophagogastric cancer (MEGCA).
147. Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: A 10-year follow-up study.
148. Metronomic therapy for heavily pretreated relapsed/refractory multiple myeloma (RRMM).
149. Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab
150. Novel Heart Failure Biomarkers Predict Improvement of Mitral Regurgitation in Patients Receiving Cardiac Resynchronization Therapy—The BIOCRT Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.